All News

The European Commission approved epcoritamab/R2 for adult patients with relapsed/refractory follicular lymphoma based on the phase 3 EPCORE FL-1 data.

The FDA declined to approve Orviglance for MRI liver imaging in patients with severe kidney impairment, requesting additional clinical data.

Paul G. Richardson, MD; and Muhamed Baljevic, MD, FACP, discussed the mechanism, synergy, tolerability, and sequencing of CELMoDs in multiple myeloma.

In this institutional retrospective review, 14.4% of clinically node-negative patients meeting SOUND trial criteria had nodal metastases on SLNB, underscoring the need for careful multidisciplinary decision-making before integrating axillary staging de-escalation into practice.

A retrospective review found progressive adoption of Choosing Wisely guidelines for sentinel lymph node biopsy omission in elderly patients with early-stage breast cancer, with younger age and earlier year of diagnosis as the strongest predictors of biopsy performance.

Four experts discussed how new breast cancer ADC trial results guide treatment sequencing, as well as practical tips for managing Dato-DXd dry eye and other adverse effects.

Imetelstat may be considered as a frontline option for patients with a high transfusion burden, said Amer Zeidan, MBBS, MD.

A primary driver of skyrocketing health care budgets has been the cost of prescription medications, which is particularly true for oncology, as personalized medicine is the standard of care.

A molecular residual disease test identified which patients with resected colorectal liver metastases gained a survival benefit from adjuvant chemotherapy.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss using CELMoDs to debulk tumor or restore T-cell fitness between T-cell–redirecting therapies in relapsed/refractory multiple myeloma.

Kim Stravers highlighted who initiates the connection with a death doula and how their role differs from that of a nurse when caring for patients with cancer.

In 58 patients undergoing excisional biopsy for discordant imaging and pathology, 16% had malignant pathology on excision; palpable lesions were the only factor independently associated with upstage to malignancy (adjusted OR 7.50).

Implementing in-office genetic testing at a diverse MedStar Georgetown breast oncology practice increased genetic counseling completion from 31.3% to 45.2% and lowered mean age at testing from 55.6 to 48.4 years, with gains across all racial groups.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed using IPSS-M criteria to detect hidden high-risk biology in lower-risk MDS.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss how sparing patients from IMiD-related GI toxicity and neutropenic infections with CELMoDs may extend treatment duration and progression-free survival.

In 167 patients with HR+/HER2− breast cancer after neoadjuvant chemotherapy, lymphovascular invasion, number of positive sentinel nodes, and >50% positive sentinel nodes were the strongest predictors of high axillary burden; a nomogram was developed to guide axillary management decisions.

This literature review of 10 studies found that anemia is common during NAC, with restrictive transfusion thresholds and intravenous iron supplementation showing favorable safety profiles, while ESA use and blood transfusions raised concerns about oncologic outcomes.

The RASolute 302 study of daraxonrasib was “the single biggest study presentation” at ASCO 2026, according to Sivraj Muralikrishnan, MD.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, discuss the immunologic and mechanistic synergy between CELMoDs and standard myeloma backbone therapies.

A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo simulation showing an 80% probability of ICG superiority.

Compared with wire-guided needle localization, MOLLI localization was associated with shorter median OR delays, fewer overall delays, and an estimated combined annual opportunity cost benefit of nearly $673,000.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discuss how long-term COMMANDS data support the use of luspatercept.

Experts focused on lymphoma cellular therapy convened to discuss CAR T-cell candidacy and practical barriers to access for patients with DLBCL.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explain how mezigdomide’s complete cereblon E3 ligase engagement overcomes IMiD resistance in heavily pretreated multiple myeloma.

Early adoption of the MOLLI wireless localization system demonstrated a rapid learning curve, fewer missed biopsy clips, and a significant reduction in operating room delays compared with traditional needle localization.

In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive increases across BI-RADS categories, supporting elastography as an adjunct to biopsy decision-making.

Amer Zeidan, MBBS, MD, discussed when to start luspatercept at the full 1.75 mg/kg dose in lower-risk MDS based on the MAXILUS trial.

Patients with clinically higher-risk disease but favorable GPS results had higher 6-year EFS rates across treatment arms vs those at a lower clinical risk.

Nicholas Hornstein, MD, PhD, ranks RASolute 302, BREAKWATER, MATTERHORN, and more in a real-time discussion on Double Blind.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.